Heart failure (HF) remains a significant global health challenge, with rising prevalence across both developed and developing regions. Beta-blockers are a foundational therapy in HF management, yet their optimal use varies across populations. This presentation examines regional prescribing patterns, dosage practices, and clinical outcomes associated with beta blocker therapy in Asian heart-failure populations, drawing on evidence from major registries and clinical trials including ASIAN-HF, DELIVER, and DAPA-HF. Findings reveal substantial disparities in beta-blocker uptake across Asia, with prescription rates ranging from 61% in Indonesia to 91% in Japan. Notably, Asian patients commonly receive significantly reduced dosages—approximately one-quarter of Western guideline recommendations—yet consistently achieve comparable improvements in left ventricular ejection fraction, hospitalization rates, and cardiovascular mortality. Safety profiles also differ meaningfully from Western cohorts, with Asian populations exhibiting lower rates of bradycardia, hypotension, and treatment discontinuation. These trends may be partially explained by pharmacogenetic differences, particularly CYP2D6 polymorphisms known to alter beta-blocker metabolism and increase drug sensitivity. Additionally, emerging evidence demonstrates that sodium-glucose cotransporter-2 (SGLT2) inhibitors, such as dapagliflozin, can be safely and effectively combined with beta-blockers, providing complementary benefits across HF phenotypes, including HFpEF. The analysis underscores an urgent need for region-specific, personalized treatment algorithms that incorporate genetic, demographic, and socioeconomic considerations. The results highlight opportunities to optimize therapeutic effectiveness, minimize adverse events, and expand the role of combination therapy in diverse Asian populations. Ultimately, this work supports a precision medicine approach to HF management that aligns dosing and pharmacologic strategy with the unique profiles of Asian patients.